News ReleasesPrinter friendly version
Protox Therapeutics to present at Invest Northwest Conference
Thursday, March 16, 2006 - Vancouver, British Columbia - Protox Therapeutics Inc.
(TSX-V: PRX) announced today
that Dr. Fahar Merchant, Protox’s Chief Executive Officer, will present at the Invest
Northwest 2006 CEO and Investor Forum to be held March 21 and 22, 2006 at the Bell
Harbor International Conference Center in Seattle, Washington.
Now in its fifth year, Invest Northwest is a leading investment forum for senior
executives from Northwest public and private life science companies to present their
company’s technology and progress to institutional investors, analysts,
investment bankers, fund managers, venture capitalists, angel investors and prospective
corporate partners.
Dr. Merchant’s presentation will take place on March 21, 2006 at 4:35p.m. PST in the Harbor Dining Room. The
presentation will also be broadcast live via an online webcast available at www.protoxtherapeutics.com. For more
information about the conference, visit the conference website at www.washbio.org.
About Protox Therapeutics
Protox Therapeutics is a product-focused development-stage company and a leader
in advancing novel, targeted protein toxin therapeutics for treatment of cancer
and other diseases. Through the company’s PORxin™ technology platform,
therapeutic candidates are generated by engineering the naturally occurring toxin, pro-aerolysin.
proaerolysin, a naturally-occurring pore-forming protoxin. These drugs become
potent anti-cancer agents when activated at a tumor site by specific proteases produced by cancer cells. Once activated,
the drug punches holes in the cancer cells causing the contents to leak out and ultimately, cell death. Protox has received
clearance from the FDA to commence Phase 1 clinical trials with the lead compound, PRX302, for the treatment of
localized prostate cancer. PRX302 is also being developed for treatment of benign prostatic hyperplasia.
Link to the webcast replay of the Invest Northwest presentation Tuesday, March 21, 2006 at 4:35PM PST
For more information, contact:
Elayne Wandler
Director, Investor Relations and Corporate Communications, Protox Therapeutics Inc.
Tel: 604-688-4369
Cell: 778-865-0172
Fax: 604-688-0173
ewandler@protoxtherapeutics.com
|
